Advertisement

Undifferentiated Pleomorphic Sarcoma (UPS; Malignant Fibrous Histiocytoma: MFH) and Myxofibrosarcoma

  • Murray F. Brennan
  • Cristina R. Antonescu
  • Robert G. Maki
Chapter

Abstract

The most common term for a generic high-grade sarcoma has evolved over the years from fibrosarcoma to malignant fibrous histiocytoma (MFH) and now to high-grade undifferentiated pleomorphic sarcoma (UPS). The new nomenclature is utilized to differentiate this tumor from tumors that are truly histiocytic, i.e., histiocytic sarcoma, recognizing that the microscopic morphology of such tumors was not specific for sarcomas. Specific varieties of what was called MFH in the past have proved to be unique entities. For example, myxofibrosarcoma is now a clearly defined sarcoma subtype that was formerly termed myxoid MFH. Myxofibrosarcoma occurs more frequently in the subcutaneous tissue and has infiltrating pattern (Fig. 7.1). Angiomatoid MFH is reclassified as angiomatoid fibrous histiocytoma, having mostly a benign clinical course and occurring in children and young adults. The situation is further complicated since the term MFH is still employed in the bone (and treated most commonly as osteogenic sarcoma in children).

Keywords

Malignant Fibrous Histiocytoma Fibrous Histiocytoma Inflammatory Myofibroblastic Tumor Histiocytic Sarcoma Embryonal Rhabdomyosarcoma 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

References

  1. 1.
    Antonescu CR, Dal Cin P, Nafa K, et al. EWSR1-CREB1 is the predominant gene fusion in angiomatoid fibrous histiocytoma. Genes Chromosomes Cancer. 2007;46(12):1051–60.PubMedCrossRefGoogle Scholar
  2. 2.
    Hallor KH, Mertens F, Jin Y, et al. Fusion of the EWSR1 and ATF1 genes without expression of the MITF-M transcript in angiomatoid fibrous histiocytoma. Genes Chromosomes Cancer. 2005;44(1):97–102.PubMedCrossRefGoogle Scholar
  3. 3.
    Romeo S, Dei Tos AP. Soft tissue tumors associated with EWSR1 translocation. Virchows Arch. 2010;456(2):219–34.PubMedCrossRefGoogle Scholar
  4. 4.
    Tanas MR, Rubin BP, Montgomery EA, et al. Utility of FISH in the diagnosis of angiomatoid fibrous histiocytoma: a series of 18 cases. Mod Pathol. 2010;23(1):93–7.PubMedCrossRefGoogle Scholar
  5. 5.
    Rubin BP, Nishijo K, Chen HI, et al. Evidence for an unanticipated relationship between undifferentiated pleomorphic sarcoma and embryonal rhabdomyosarcoma. Cancer Cell. 2011;19(2):177–91.PubMedCrossRefGoogle Scholar
  6. 6.
    Sleijfer S, Ouali M, van Glabbeke M, et al. Prognostic and predictive factors for outcome to first-line ifosfamide-containing chemotherapy for adult patients with advanced soft tissue sarcomas: an exploratory, retrospective analysis on large series from the European organization for research and treatment of cancer-soft tissue and bone sarcoma group (EORTC-STBSG). Eur J Cancer. 2010;46(1):72–83.PubMedCrossRefGoogle Scholar
  7. 7.
    Maki RG, Wathen JK, Patel SR, et al. Randomized phase II study of gemcitabine and docetaxel compared with gemcitabine alone in patients with metastatic soft tissue sarcomas: results of sarcoma alliance for research through collaboration study 002 [corrected]. J Clin Oncol. 2007;25(19):2755–63.PubMedCrossRefGoogle Scholar
  8. 8.
    Hainsworth JD, Carrell D, Drengler RL, et al. Weekly combination chemotherapy with docetaxel and gemcitabine as first-line treatment for elderly patients and patients with poor performance status who have extensive-stage small cell lung carcinoma: a Minnie Pearl Cancer Research Network phase II trial. Cancer. 2004;100(11):2437–41.PubMedCrossRefGoogle Scholar
  9. 9.
    O’Shaughnessy JA, Pluenneke R, Sternberg J, et al. Phase II trial of weekly docetaxel/gemcitabine as first-line chemotherapy in patients with locally recurrent or metastatic breast cancer. Clin Breast Cancer. 2006;6(6):505–10.PubMedCrossRefGoogle Scholar
  10. 10.
    Dileo P, Morgan JA, Zahrieh D, et al. Gemcitabine and vinorelbine combination chemotherapy for patients with advanced soft tissue sarcomas: results of a phase II trial. Cancer. 2007;109(9):1863–9.PubMedCrossRefGoogle Scholar
  11. 11.
    Garcia-Del-Muro X, Lopez-Pousa A, Maurel J, et al. Randomized phase II study comparing gemcitabine plus dacarbazine versus dacarbazine alone in patients with previously treated soft tissue sarcoma: a Spanish Group for Research on Sarcomas study. J Clin Oncol. 2011;29(18):2528–33.PubMedCrossRefGoogle Scholar
  12. 12.
    Schoffski P, Ray-Coquard IL, Cioffi A, et al. Activity of eribulin mesylate in patients with soft-tissue sarcoma: a phase 2 study in four independent histological subtypes. Lancet Oncol. 2011;12(11):1045–52.PubMedCrossRefGoogle Scholar
  13. 13.
    Chugh R, Wathen JK, Maki RG, et al. Phase II multicenter trial of imatinib in 10 histologic subtypes of sarcoma using a bayesian hierarchical statistical model. J Clin Oncol. 2009;27(19):3148–53.PubMedCrossRefGoogle Scholar
  14. 14.
    D’Adamo DR, Keohan M, Schuetze S, et al. Clinical results of a phase II study of sorafenib in patients (pts) with non-GIST sarcomas (CTEP study #7060). J Clin Oncol. 2007; 25(18S): Abstr 10001.Google Scholar
  15. 15.
    George S, Merriam P, Maki RG, et al. Multicenter phase II trial of sunitinib in the treatment of nongastrointestinal stromal tumor sarcomas. J Clin Oncol. 2009;27(19):3154–60.PubMedCrossRefGoogle Scholar
  16. 16.
    Sleijfer S, Ray-Coquard I, Papai Z, et al. Pazopanib, a multikinase angiogenesis inhibitor, in patients with relapsed or refractory advanced soft tissue sarcoma: a phase II study from the European organisation for research and treatment of cancer-soft tissue and bone sarcoma group (EORTC study 62043). J Clin Oncol. 2009;27(19):3126–32.PubMedCrossRefGoogle Scholar
  17. 17.
    Gortzak E, Azzarelli A, Buesa J, et al. A randomised phase II study on neo-adjuvant chemotherapy for ‘high-risk’ adult soft-tissue sarcoma. Eur J Cancer. 2001;37(9):1096–103.PubMedCrossRefGoogle Scholar
  18. 18.
    Woll PJ, Van Glabbeke M, Hohenberger P, et al. Adjuvant chemotherapy with doxorubicin and ifosfamide in resected soft tissue sarcoma: interim analysis of a randomised phase III trial. J Clin Oncol. 2007; 25(18S): Abstr 10008.Google Scholar
  19. 19.
    Frustaci S, Gherlinzoni F, De Paoli A, et al. Adjuvant chemotherapy for adult soft tissue sarcomas of the extremities and girdles: results of the Italian randomized cooperative trial. J Clin Oncol. 2001;19(5):1238–47.PubMedGoogle Scholar
  20. 20.
    Frustaci S, De Paoli A, Bidoli E, et al. Ifosfamide in the adjuvant therapy of soft tissue sarcomas. Oncology. 2003;65 Suppl 2:80–4.PubMedCrossRefGoogle Scholar
  21. 21.
    Pervaiz N, Colterjohn N, Farrokhyar F, et al. A systematic meta-analysis of randomized controlled trials of adjuvant chemotherapy for localized resectable soft-tissue sarcoma. Cancer. 2008;113(3):573–81.PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media New York 2013

Authors and Affiliations

  • Murray F. Brennan
    • 1
  • Cristina R. Antonescu
    • 2
  • Robert G. Maki
    • 3
  1. 1.International Center & Department of SurgeryMemorial Sloan-Kettering Cancer CenterNew YorkUSA
  2. 2.Department of PathologyMemorial Sloan-Kettering Cancer CenterNew YorkUSA
  3. 3.Departments of Medicine Pediatrics, and OrthopaedicsMount Sinai School of MedicineNew YorkUSA

Personalised recommendations